Free Trial
→ SpaceX is offering you shares. Don't take them. (From Behind the Markets) (Ad)tc pixel Free VAXX Stock Alerts

Vaxxinity (VAXX) Competitors

Vaxxinity logo
$0.0002 +0.00 (+100.00%)
As of 11:07 AM Eastern
Compare

VAXX vs. SCPS, ARDS, NAVB, PXMD, and GNCA

Should you buy Vaxxinity stock or one of its competitors? MarketBeat compares Vaxxinity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vaxxinity include Scopus BioPharma (SCPS), Aridis Pharmaceuticals (ARDS), Navidea Biopharmaceuticals (NAVB), PaxMedica (PXMD), and Genocea Biosciences (GNCA). These companies are all part of the "pharmaceutical products" industry.

How does Vaxxinity compare to Scopus BioPharma?

Vaxxinity (NASDAQ:VAXX) and Scopus BioPharma (NASDAQ:SCPS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, media sentiment, analyst recommendations, risk and dividends.

Vaxxinity has a beta of -74.37, indicating that its share price is 7,537% less volatile than the broader market. Comparatively, Scopus BioPharma has a beta of -0.14, indicating that its share price is 114% less volatile than the broader market.

In the previous week, Scopus BioPharma had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for Scopus BioPharma and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 equaled Scopus BioPharma'saverage media sentiment score.

Company Overall Sentiment
Vaxxinity Neutral
Scopus BioPharma Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxxinityN/AN/A-$56.93M-$0.45N/A
Scopus BioPharmaN/AN/A-$11.61MN/AN/A

82.9% of Vaxxinity shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 5.1% of Scopus BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
VaxxinityN/A N/A N/A
Scopus BioPharma N/A N/A N/A

Summary

Scopus BioPharma beats Vaxxinity on 3 of the 5 factors compared between the two stocks.

How does Vaxxinity compare to Aridis Pharmaceuticals?

Aridis Pharmaceuticals (NASDAQ:ARDS) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Company Net Margins Return on Equity Return on Assets
Aridis PharmaceuticalsN/A N/A N/A
Vaxxinity N/A N/A N/A

Vaxxinity is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.00
VaxxinityN/AN/A-$56.93M-$0.45N/A

Aridis Pharmaceuticals has a beta of 49.37, suggesting that its share price is 4,837% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -74.37, suggesting that its share price is 7,537% less volatile than the broader market.

In the previous week, Aridis Pharmaceuticals' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Aridis Pharmaceuticals Neutral
Vaxxinity Neutral

9.6% of Aridis Pharmaceuticals shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 5.5% of Aridis Pharmaceuticals shares are held by insiders. Comparatively, 64.1% of Vaxxinity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Aridis Pharmaceuticals beats Vaxxinity on 4 of the 6 factors compared between the two stocks.

How does Vaxxinity compare to Navidea Biopharmaceuticals?

Navidea Biopharmaceuticals (NYSE:NAVB) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Navidea Biopharmaceuticals Neutral
Vaxxinity Neutral

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 82.9% of Vaxxinity shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by insiders. Comparatively, 64.1% of Vaxxinity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Company Net Margins Return on Equity Return on Assets
Navidea BiopharmaceuticalsN/A N/A N/A
Vaxxinity N/A N/A N/A

Navidea Biopharmaceuticals has higher revenue and earnings than Vaxxinity. Vaxxinity is trading at a lower price-to-earnings ratio than Navidea Biopharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

Navidea Biopharmaceuticals has a beta of 1.76, indicating that its share price is 76% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -74.37, indicating that its share price is 7,537% less volatile than the broader market.

Summary

Navidea Biopharmaceuticals beats Vaxxinity on 4 of the 7 factors compared between the two stocks.

How does Vaxxinity compare to PaxMedica?

Vaxxinity (NASDAQ:VAXX) and PaxMedica (NASDAQ:PXMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Vaxxinity is trading at a lower price-to-earnings ratio than PaxMedica, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
VaxxinityN/AN/A-$56.93M-$0.45N/A
PaxMedicaN/AN/A-$18.29M-$6.09N/A

Vaxxinity's return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
VaxxinityN/A N/A N/A
PaxMedica N/A -3,167.89%-560.35%

Vaxxinity has a beta of -74.37, meaning that its stock price is 7,537% less volatile than the broader market. Comparatively, PaxMedica has a beta of -0.99, meaning that its stock price is 199% less volatile than the broader market.

82.9% of Vaxxinity shares are held by institutional investors. Comparatively, 4.9% of PaxMedica shares are held by institutional investors. 64.1% of Vaxxinity shares are held by company insiders. Comparatively, 1.0% of PaxMedica shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, PaxMedica had 1 more articles in the media than Vaxxinity. MarketBeat recorded 1 mentions for PaxMedica and 0 mentions for Vaxxinity. Vaxxinity's average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

Company Overall Sentiment
Vaxxinity Neutral
PaxMedica Neutral

Summary

Vaxxinity beats PaxMedica on 5 of the 9 factors compared between the two stocks.

How does Vaxxinity compare to Genocea Biosciences?

Genocea Biosciences (NASDAQ:GNCA) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

0.6% of Genocea Biosciences shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 1.6% of Genocea Biosciences shares are owned by company insiders. Comparatively, 64.1% of Vaxxinity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genocea Biosciences has higher revenue and earnings than Vaxxinity. Vaxxinity is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genocea Biosciences$1.91M0.00-$33.20M-$0.61N/A
VaxxinityN/AN/A-$56.93M-$0.45N/A

Vaxxinity's return on equity of 0.00% beat Genocea Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Genocea BiosciencesN/A -182.88% -62.76%
Vaxxinity N/A N/A N/A

Genocea Biosciences has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market. Comparatively, Vaxxinity has a beta of -74.37, indicating that its share price is 7,537% less volatile than the broader market.

In the previous week, Genocea Biosciences' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score.

Company Overall Sentiment
Genocea Biosciences Neutral
Vaxxinity Neutral

Summary

Vaxxinity beats Genocea Biosciences on 6 of the 9 factors compared between the two stocks.

Get Vaxxinity News Delivered to You Automatically

Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VAXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

VAXX vs. The Competition

Export
MetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$25K$992.36M$6.30B$12.44B
Dividend YieldN/A4.84%2.69%5.33%
P/E Ratio0.001.0120.3122.64
Price / SalesN/A122.18518.49115.68
Price / CashN/A20.0641.3955.53
Price / Book0.008.129.986.72
Net Income-$56.93M-$3.91M$3.56B$337.03M
7 Day PerformanceN/A-1.73%-0.89%0.09%
1 Month PerformanceN/AN/AN/A-1.78%
1 Year PerformanceN/A111.96%28.76%33.98%

Vaxxinity Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VAXX
Vaxxinity
N/A$0.00
+100.0%		N/A+100.0%$25KN/AN/A90
SCPS
Scopus BioPharma
N/A$0.00
flat		N/A+100.0%$17KN/AN/A9
ARDS
Aridis Pharmaceuticals
N/A$0.00
-88.2%		N/A+100.0%$11KN/A0.0030
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10
PXMD
PaxMedica
N/A$0.00
+40.0%		N/AN/A$8KN/AN/A2

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VAXX) was last updated on 6/4/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX is set to go public as soon as June 11, with OpenAI and Anthropic likely to follow. Whitney Tilson - Ha...
Stansberry Research | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
Trump’s secret China deal
Trump just returned from Beijing with the most powerful business delegation in American history - Elon Musk, J...
Porter & Company | Sponsoredtc pixel
Giving “2022 pre-ChatGPT” vibes (but 10x bigger)
When ChatGPT launched in 2022, Nvidia surged 1,800% over three years. Now, Nvidia's CEO suggests July 22nd cou...
StocksToTrade | Sponsoredtc pixel
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...
Behind the Markets | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Where did Vanguard quietly put $101 billion?
A new Gallup poll shows 70% of Americans want AI data centers kept out of their communities - and futurist Geo...
Eagle Publishing | Sponsoredtc pixel